HEPCIDIN ANALOGUES AND USES THEREOF

• US 20190185535A1
• Filed: 07/17/2018
• Published: 06/20/2019
• Est. Priority Date: 03/15/2013
• Status: Active Grant

• Current Assignee: Protagonist Therapeutics, Inc.
• Original Assignee: Protagonist Therapeutics, Inc.
• Inventors: Smythe, Mark Leslie, Bourne, Gregory Thomas, Vink, Simone, Frederick, Brian Troy, Madala, Praveen, Tofteng Shelton, Anne Pernille, Fog, Jacob Ulrik
• Granted Patent: US 10,442,846 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/12 for electrolyte homeostasis
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695

Abstract

The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.

Claims

1. A peptide having the following structural formula I′

R¹′

—

X′

—

Y′

—

R² 

 

(I′

) (SEQ ID NO;

21)

or a pharmaceutically acceptable salt or solvate thereof,

wherein

R^1′

is hydrogen, an C₁-C₆ alkyl, C₆-C₁₂ aryl, C₆-C₁₂ aryl C₁-C₆ alkyl, C₁-C₂₀ alkanoyl (e.g. methyl, acetyl, formyl, benzoyl or trifluoroacetyl, isovaleric acid, isobutyric acid, octanoic acid, lauric acid and hexadecanoic acid), γ

-Glu-hexadecanoic acid) or pGlu, appended to the N-terminus, and including PEGylated versions (e.g. PEG3 to PEG11), alone or as spacers of any of the foregoing;

R²′

is —

NH₂ or —

OH;

X′

is a peptide sequence having the formula Ia′

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10 

 

(Ia′

) (SEQ ID NO;

     13)

wherein

X1 is Asp, Glu, Ala, Gly, Thr, Ida, pGlu, bhAsp, D-Asp, Tyr, Leu or absent;

X2 is Thr, Ala, Aib, D-Thr, Arg or absent;

X3 is His, Ala, D-His or Lys;

X4 is Phe, Ala, Dpa, bhPhe or D-Phe;

X5 is Pro, Glu, Ser, Gly, Arg, Lys, Val, Ala, D-Pro, bhPro, Sarc, Abu or absent;

X6 is Ile, Cys, Arg, Leu, Lys, His, Glu, D-Ile, D-Arg, D-Cys, Val, Ser or Ala;

X7 is Cys, Ile, Ala, Leu, Val, Ser, Phe, Dapa, D-Ile or D-Cys;

X8 is Ile, Lys, Arg, Ala, Gln, Phe, Glu, Asp, Tyr, Ser, Leu, Val, D-Ile, D-Lys, D-Arg, or Dapa;

X9 is Phe, Ala, Ile, Tyr, Lys, Arg, bhPhe or D-Phe; and

X10 is Lys, Phe or absent;

and provided that if Y′

is absent, X7 is Ile;

Y′

is a peptide having the formula IIa′

Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Y9-Y10-Y11-Y12-Y13-Y14-Y15 

 

(IIa′

) (SEQ ID NO;

     16)

wherein

Y1 is Gly, Cys, Ala, Phe, Pro, Glu, Lys, D-Pro, Val, Ser or absent;

Y2 is Pro, Ala, Cys, Gly or absent;

Y3 is Arg, Lys, Pro, Gly, His, Ala, Trp or absent;

Y4 is Ser, Arg, Gly, Trp, Ala, His, Tyr or absent;

Y5 is Lys, Met, Arg, Ala or absent;

Y6 is Gly, Ser, Lys, Ile, Ala, Pro, Val or absent;

Y7 is Trp, Lys, Gly, Ala Ile, Val or absent;

Y8 is Val, Thr, Gly, Cys, Met, Tyr, Ala, Glu, Lys, Asp, Arg or absent;

Y9 is Cys, Tyr or absent;

Y10 is Met, Lys, Arg, Tyr or absent;

Y11 is Arg, Met, Cys, Lys or absent;

Y12 is Arg, Lys, Ala or absent;

Y13 is Arg, Cys, Lys, Val or absent;

Y14 is Arg, Lys, Pro, Cys, Thr or absent; and

Y15 is Thr, Arg or absent;

wherein said compound of formula I′

is optionally PEGylated on R^1′

, X′

, or Y′

; and

wherein when said compound of formula I′

comprises two or more cysteine residues, at least two of said cysteine residues being linked via a disulfide bond.

2. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein R^1′

is hydrogen, isovaleric acid, isobutyric acid or acetyl.

3. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein X′

is a peptide having formula Ia′ and

wherein

X1 is Asp, Ala, Ida, pGlu, bhAsp, Leu, D-Asp or absent;

X2 is Thr, Ala, or D-Thr;

X3 is His, Lys, D-His or Lys;

X4 is Phe, Ala, Dpa or D-Phe;

X5 is Pro, Gly, Arg, Lys, Ala, D-Pro or bhPro;

X6 is Ile, Cys, Arg, Lys, D-Ile or D-Cys;

X7 is Cys, Ile, Leu, Val, Phe, D-Ile or D-Cys;

X8 is Ile, Arg, Phe, Gln, Lys, Glu, Val, Leu or D-Ile;

X9 is Phe or bhPhe; and

X10 is Lys, Phe or absent.

4. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein X′

is a peptide having formula Ib′

X1-Thr-His-X4-X5-X6-X7-X8-Phe-X10 

 

(Ib′

) (SEQ ID NO;

     14)

wherein

X1 is Asp, Ida, pGlu, bhAsp or absent;

X4 is Phe or Dpa;

X5 is Pro or bhPro;

X6 is Ile, Cys or Arg;

X7 is Cys, Ile, Leu or Val;

X8 is Ile, Lys, Glu, Phe, Gln or Arg; and

X10 is Lys or absent.

5. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein X′

is a peptide having formula Ic′

X1-Thr-His-X4-X5-Cys-Ile-X8-Phe-X10 

 

(Ic′

) (SEQ ID NO;

     15)

wherein

X1 is Asp, Ida, pGlu, bhAsp or absent;

X4 is Phe or Dpa;

X5 is Pro or bhPro;

X8 is Ile, Lys, Glu, Phe, Gln or Arg; and

X10 is Lys or absent.

6. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein Y′

is a peptide having formula IIb′

Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Cys-Y10 

 

(IIb′

) (SEQ ID NO;

     17)

wherein

Y1 is Gly, Ala, Lys, Pro or D-Pro;

Y2 is Pro, Ala or Gly;

Y3 is Arg, Ala, Lys or Trp;

Y4 is Ser, Gly or Ala;

Y5 is Lys, Met, Arg or Ala;

Y6 is Gly, Arg or Ala;

Y7 is Trp or Ala;

Y8 is Val, Thr, Ala or Glu; and

Y10 is Met, Lys or absent.

7. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein Y′

is a peptide having formula IIc′

Y1-Y2-Y3-Ser-Lys-Gly-Trp-Y8-Cys-Y10 

 

(IIc′

) (SEQ ID NO;

18)

wherein

Y1 is Gly, Pro or D-Pro;

Y2 is Pro or Gly;

Y3 is Arg or Lys;

Y8 is Val or Thr; and

Y10 is Met, Lys or absent.

8. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein Y′

is a peptide having the formula IId′

Y1-Cys-Y3-Y4-Arg-Y6-Y7-Y8-Cys-Y10-Y11-Y12-Y13-Y14-Y15 

 

(IId′

) (SEQ ID NO;

     19)

wherein

Y1 is Val or Ala or absent;

Y3 is Gly, Pro or absent;

Y4 is His, Trp or Tyr;

Y6 is Ser, Gly or Pro;

Y7 is Ile, Gly or Lys;

Y8 is Gly, Met or absent;

Y10 is Tyr or Cys;

Y11 is Arg, Lys, Met or Ala;

Y12 is Arg or Ala;

Y13 is Cys or Val or absent;

Y14 is Cys, Lys, Pro, Arg, Thr or absent; and

Y15 is Arg, Thr or absent.

9. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein Y′

is a peptide having the formula IIe′

Val-Cys-Y3-His-Arg-Y6-Y7-Y8-Cys-Tyr-Arg-Y12-Y13-Y14-Y15 

 

(IIe′

) (SEQ ID NO;

20)

wherein

Y3 is Gly or absent;

Y6 is Ser or Pro;

Y7 is Ile or Lys;

Y8 is Gly or absent;

Y12 is Arg or Ala;

Y13 is Cys or Val or absent;

Y14 is Cys, Arg, Thr or absent; and

Y15 is Arg or absent.

18. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein the peptide exhibits hepcidin activity.

19. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein the peptide binds ferroportin.

20. A composition which comprises at least one peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1.

22. A method of treating a disease of iron metabolism in a subject which comprises administering at least one peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1 or the composition according to claim 20 to the subject.

23. The method of claim 22, wherein the disease of iron metabolism is an iron overload disease.

57. The method of claim 22, wherein the disease of iron metabolism is hereditary hemochromatosis, iron hemochromatosis, HFE (High Iron Fe) mutation hemochromatosis, ferroportin mutation hemochromatosis, transferrin receptor 2 mutation hemochromatosis, hemojuvelin mutation hemochromatosis, hepcidin mutation hemochromatosis, juvenile hemochromatosis, neonatal hemochromatosis, hepcidin deficiency, transfusional iron overload, or thalassemia.

58. The method of claim 57, wherein the disease of iron metabolism is a thalassemia.

59. The method of claim 58, wherein the thalassemia is thalassemia intermedia, alpha thalassemia, or β

-thalassemia.

60. The method of claim 59, wherein the disease of iron metabolism is β

-thalassemia.

61. The method of claim 57, wherein the disease of iron metabolism is hereditary hemochromatosis (HH).

10-17. -17. (canceled)

21. (canceled)

24-56. -56. (canceled)